JP2009530612A5 - - Google Patents

Download PDF

Info

Publication number
JP2009530612A5
JP2009530612A5 JP2009500462A JP2009500462A JP2009530612A5 JP 2009530612 A5 JP2009530612 A5 JP 2009530612A5 JP 2009500462 A JP2009500462 A JP 2009500462A JP 2009500462 A JP2009500462 A JP 2009500462A JP 2009530612 A5 JP2009530612 A5 JP 2009530612A5
Authority
JP
Japan
Prior art keywords
subject
gelsolin
risk
level
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009500462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009530612A (ja
JP5322917B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/006451 external-priority patent/WO2007109056A2/en
Publication of JP2009530612A publication Critical patent/JP2009530612A/ja
Publication of JP2009530612A5 publication Critical patent/JP2009530612A5/ja
Application granted granted Critical
Publication of JP5322917B2 publication Critical patent/JP5322917B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009500462A 2006-03-15 2007-03-15 炎症性疾患の診断および処置のためのゲルゾリンの使用 Active JP5322917B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78250806P 2006-03-15 2006-03-15
US60/782,508 2006-03-15
PCT/US2007/006451 WO2007109056A2 (en) 2006-03-15 2007-03-15 Use of gelsolin to diagnose and treat inflammatory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011270249A Division JP2012083359A (ja) 2006-03-15 2011-12-09 炎症性疾患の診断および処置のためのゲルゾリンの使用

Publications (3)

Publication Number Publication Date
JP2009530612A JP2009530612A (ja) 2009-08-27
JP2009530612A5 true JP2009530612A5 (cg-RX-API-DMAC10.html) 2011-04-14
JP5322917B2 JP5322917B2 (ja) 2013-10-23

Family

ID=38522935

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009500462A Active JP5322917B2 (ja) 2006-03-15 2007-03-15 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2011270249A Withdrawn JP2012083359A (ja) 2006-03-15 2011-12-09 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2014071355A Withdrawn JP2014122924A (ja) 2006-03-15 2014-03-31 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2015137491A Active JP6198777B2 (ja) 2006-03-15 2015-07-09 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2017098198A Active JP6568144B2 (ja) 2006-03-15 2017-05-17 炎症性疾患の診断および処置のためのゲルゾリンの使用

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2011270249A Withdrawn JP2012083359A (ja) 2006-03-15 2011-12-09 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2014071355A Withdrawn JP2014122924A (ja) 2006-03-15 2014-03-31 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2015137491A Active JP6198777B2 (ja) 2006-03-15 2015-07-09 炎症性疾患の診断および処置のためのゲルゾリンの使用
JP2017098198A Active JP6568144B2 (ja) 2006-03-15 2017-05-17 炎症性疾患の診断および処置のためのゲルゾリンの使用

Country Status (13)

Country Link
US (3) US8198094B2 (cg-RX-API-DMAC10.html)
EP (2) EP3279663B1 (cg-RX-API-DMAC10.html)
JP (5) JP5322917B2 (cg-RX-API-DMAC10.html)
KR (2) KR20140091048A (cg-RX-API-DMAC10.html)
CN (2) CN107085113B (cg-RX-API-DMAC10.html)
AU (1) AU2007227613A1 (cg-RX-API-DMAC10.html)
CA (1) CA2680413C (cg-RX-API-DMAC10.html)
DK (2) DK2001496T3 (cg-RX-API-DMAC10.html)
ES (2) ES2641879T3 (cg-RX-API-DMAC10.html)
HU (2) HUE035884T2 (cg-RX-API-DMAC10.html)
PL (2) PL2001496T3 (cg-RX-API-DMAC10.html)
PT (2) PT3279663T (cg-RX-API-DMAC10.html)
WO (1) WO2007109056A2 (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
CN1980694B (zh) * 2004-05-12 2012-09-26 布赖汉姆妇女医院有限公司 凝溶胶蛋白治疗感染的用途
JP4348631B2 (ja) * 2005-03-29 2009-10-21 セイコーエプソン株式会社 半導体素子の製造方法
JP2009530613A (ja) 2006-03-15 2009-08-27 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用
US8198094B2 (en) 2006-03-15 2012-06-12 The Brigham And Women's Hospital, Inc. Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis
US20070282376A1 (en) 2006-06-06 2007-12-06 Shuros Allan C Method and apparatus for neural stimulation via the lymphatic system
US7526337B2 (en) * 2006-06-06 2009-04-28 Cardiac Pacemakers, Inc. Method and device for lymphatic system monitoring
US7734341B2 (en) 2006-06-06 2010-06-08 Cardiac Pacemakers, Inc. Method and apparatus for gastrointestinal stimulation via the lymphatic system
US8905999B2 (en) 2006-09-01 2014-12-09 Cardiac Pacemakers, Inc. Method and apparatus for endolymphatic drug delivery
US8367356B2 (en) * 2007-08-15 2013-02-05 Beijing Cotimes Biotech Co., Ltd. Gelsolin binding agent compositions and uses of same
EP2708603B1 (en) * 2008-01-25 2017-04-19 The General Hospital Corporation Diagnostic and therapeutic uses of gelsolin in renal failure
EP2311823A1 (en) * 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
DE102010026500A1 (de) * 2010-07-07 2012-01-12 Arthrogen Gmbh Verfahren zur Herstellung von autologen Proteinen
BR112015000174A2 (pt) * 2012-07-05 2017-06-27 Taiwan Liposome Co Ltd método para o tratamento da artrite
KR101416954B1 (ko) * 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
US10161006B2 (en) 2014-03-11 2018-12-25 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Diagnosis of hematologic diseases
WO2016033187A1 (en) * 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease
WO2016040987A1 (en) * 2014-09-15 2016-03-24 Abregen Pty Ltd Treating and/or preventing psoriasis
IT201700083044A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
WO2021102235A1 (en) 2019-11-21 2021-05-27 The Regents Of The University Of Michigan Use of gelsolin to treat or prevent lung injury and disease
US11266376B2 (en) 2020-06-19 2022-03-08 Ultrasound Ai Inc. Premature birth prediction
US12369883B2 (en) 2020-06-19 2025-07-29 Ultrasound AI, Inc. Artificial intelligence system for determining clinical values through medical imaging
CA3196026A1 (en) * 2020-09-23 2022-03-31 Bioaegis Therapeutics Inc. Compositions and methods for identifying and treating microparticle-associated diseases and conditions
EP4217374A1 (en) * 2020-09-25 2023-08-02 The Francis Crick Institute Limited Immunotherapy
CN112630430B (zh) * 2020-11-16 2021-08-27 北京美联泰科生物技术有限公司 一种定量检测uchl-1的试剂盒及其应用
KR20250161553A (ko) * 2023-03-13 2025-11-17 울트라사운드 에이아이, 인코포레이티드 의료 이미징을 통한 포괄적인 의료 진단, 예후, 및 치료 최적화를 위한 인공 지능 시스템

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
CA2016227A1 (en) 1989-05-18 1990-11-18 Xandra O. Breakefield Genetic diagnosis of torsion dystonia
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
ES2124702T3 (es) 1990-04-11 1999-02-16 Brigham & Womens Hospital Usos terapeuticos de compuestos que se unen a actina.
CA2063593A1 (en) 1990-05-04 1991-11-05 Biogen, Inc. Multimeric gelsolin fusion constructs
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5360350A (en) 1991-08-23 1994-11-01 The Whitaker Corporation Sealant compositions and sealed electrical connectors
CA2141600A1 (en) 1992-08-03 1994-02-17 Richard U. Margolis Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
US5691160A (en) 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
EP0675967A4 (en) 1992-10-01 1999-04-28 Gen Hospital Corp Functional assay for tumor suppressor genes.
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US5830436A (en) 1993-03-30 1998-11-03 Duke University Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
AU1269495A (en) 1994-01-10 1995-08-01 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
AU686780B2 (en) 1994-03-11 1998-02-12 Merck & Co., Inc. Composition for the treatment of lung disease
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
DE69512930T2 (de) 1994-10-27 2000-05-18 Merck Frosst Canada & Co., Halifax Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5563153A (en) 1995-02-22 1996-10-08 University Of Kansas Medical Center Sterile topical anesthetic gel
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5774303A (en) 1995-03-24 1998-06-30 Stormedia, Inc. Sputter induced micro-texturing enhancement for magnetic head structures
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5804427A (en) 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5925529A (en) 1995-06-07 1999-07-20 The Regents Of The University Of California Method for discovery of peptide agonists
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
US5789413A (en) 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
GB9607503D0 (en) 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5922742A (en) 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5677318A (en) 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
AU3817497A (en) 1996-07-30 1998-02-20 Biogen, Inc. Production of recombinant plasma gelsolin containing a disulfide bond
DK0941108T3 (da) 1996-12-04 2002-11-18 Renovo Ltd Sårheling og behandling af fibrose
WO1998043630A1 (en) * 1997-04-02 1998-10-08 Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
IL148841A0 (en) * 1999-10-06 2002-09-12 Basf Ag INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αvβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
WO2002059604A2 (en) * 2001-01-26 2002-08-01 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
NZ528076A (en) 2001-03-02 2005-09-30 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules
EP1249244A1 (en) 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
DE60233414D1 (de) 2001-07-09 2009-10-01 Combinatorx Inc Kombinationen für die behandlung entzündlicher erkrankungen
CA2458677A1 (en) 2001-08-30 2003-03-13 Praecis Pharmaceuticals Incorporated Methods and compositions for treating inflammatory disorders
US20080051348A1 (en) 2002-02-06 2008-02-28 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
EP2266595A3 (en) 2002-02-06 2011-07-06 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
WO2003088811A2 (en) 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
WO2004001421A2 (en) 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
KR20050114217A (ko) 2003-02-21 2005-12-05 메드벳 싸이언스 피티와이. 리미티드 진단 및 치료 방법
US20050048574A1 (en) * 2003-03-14 2005-03-03 Kantor Aaron B. Biomarkers for diagnosing rheumatoid arthritis
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US20070238655A1 (en) 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
CA2550833A1 (en) 2003-12-22 2005-07-14 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
ES2541683T3 (es) 2004-02-27 2015-07-23 F. Hoffmann-La Roche Ag Método para evaluar la artritis reumatoide mediante la medición del factor reumatoide y la interleuquina-6
CN1980694B (zh) 2004-05-12 2012-09-26 布赖汉姆妇女医院有限公司 凝溶胶蛋白治疗感染的用途
SG183012A1 (en) 2004-06-04 2012-08-30 Genentech Inc Method for treating multiple sclerosis
DK1929297T3 (da) 2005-09-29 2013-03-04 Caprion Proteomics Usa Llc Biomarkører for dissemineret sklerose og fremgangsmåder til anvendelse heraf
US8198094B2 (en) 2006-03-15 2012-06-12 The Brigham And Women's Hospital, Inc. Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis
JP2009530613A (ja) 2006-03-15 2009-08-27 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用
EP2708603B1 (en) 2008-01-25 2017-04-19 The General Hospital Corporation Diagnostic and therapeutic uses of gelsolin in renal failure
KR101568323B1 (ko) 2014-01-08 2015-11-12 한국원자력의학원 겔솔린을 유효성분으로 포함하는 수지상세포 분화 유도용 조성물 및 이의 분화 유도방법
WO2016033187A1 (en) 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease

Similar Documents

Publication Publication Date Title
JP2009530613A5 (cg-RX-API-DMAC10.html)
Nofal et al. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control.
Nadarajah et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD)
Kircik et al. Anti-TNF agents for the treatment of psoriasis
JP2021513077A5 (cg-RX-API-DMAC10.html)
Ying et al. Water treadmill training attenuates blood-spinal cord barrier disruption in rats by promoting angiogenesis and inhibiting matrix metalloproteinase-2/9 expression following spinal cord injury
JP2016522164A5 (cg-RX-API-DMAC10.html)
Santana et al. Trehalose alleviates the phenotype of Machado–Joseph disease mouse models
JP2020533381A5 (cg-RX-API-DMAC10.html)
Lee et al. Relationship between ventricular characteristics on brain computed tomography and 6-month neurologic outcome in cardiac arrest survivors who underwent targeted temperature management
EP1444516A4 (en) USE OF LEPTIN FOR THE TREATMENT OF LIPOATROPHY IN HUMANS AND METHOD FOR DETERMINING A PRESENTATION POSITION AGAINST TREATMENT
Dufour et al. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease
CN110496124A (zh) 治疗脉管畸形的化合物
Shin et al. Effects of topical amphotericin B on expression of cytokines in nasal polyps
Arnaoutakis et al. Serum levels of neuron-specific ubiquitin carboxyl-terminal esterase-L1 predict brain injury in a canine model of hypothermic circulatory arrest
TWI517852B (zh) 微小ＲＮＡ ｍｉＲ－１９９ａ－５ｐ之用途
Stock et al. S86 Serum biomarkers in SSc-ILD: association with presence, severity and prognosis
WO2005030265A3 (en) Optical imaging of endometriosis
Li et al. Effect of combination of parenteral edaravone and nimodipine on ischemic cerebral injury following cerebral hemorrhage
Yang et al. Association of Circulating Cell‐Free Mitochondrial DNA With Sudden Sensorineural Hearing Loss
JP2021521437A5 (cg-RX-API-DMAC10.html)
James et al. Targeting the Signaling Domain of Aminopeptidase N Ameliorates Pulmonary Hypertension
BASHARAT IMPACT OF EARLY TREATMENT ON HEALTHCARE UTILIZATION AND RISK OF OSTEOARTHRITIS IN PSORIASIS PATIENTS
Vodošek Hojs et al. MO147 ASSOCIATION OF CHA2DS2-VASC SCORE WITH CAROTID-FEMORAL PULSE WAVE VELOCITY IN CHRONIC KIDNEY DISEASE PATIENTS
Saita PS-C26-8: UNIQUE PROPERTIES OF DEPRESSOR, RENAL, AND ALDOSTERONE RESPONSES TO ALISKIREN THERAPY IN HYPERTENSIVE PATIENTS WITH NEPHROPATHY